Company Information
Shire: Pipeline • Products • Performance • Potential
| Publication Date | December 2008 |
| Publisher | Espicom |
| Product Type | |
| Pages | 76 |
| ISBN Number | not applicable |
| Product Code | ESP01047 |
Price
approximately: $901 | €664
Order above formats by FAX
Summary
Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
Shire is a leading specialty pharmaceutical company traditionally focused on the treatment of attention deficit hyperactivity disorder (ADHD) and gastrointestinal disorders. In 2005, Shire completed the acquisition of Transkaryotic Therapies, broadening the company's focus into the treatment of genetic and renal diseases. In 2007, Shire purchased New River Pharmaceuticals leading to a significant expansion of Shire's ADHD product portfolio and pipeline. The company's headquarters are based in the UK, however, during its 20 years of operation, Shire has established a significant presence throughout Europe and in the US.
Following the approval by shareholders at the Annual General Meeting on 24th September 2008, Shire Limited has changed its name to Shire plc with effect from 1st October 2008.
In the last five years, Shire has spent over US$8 billion on acquisitions which have seen the company considerably expand its global presence and areas of interest. Most importantly, these acquisitions have added four key products to a portfolio that was becoming dated and facing threats to its intellectual property. The addition of Vyvanse (from New River Pharmaceuticals) will help further cement the company's position as a leader in the treatment of attention deficit hyperactivity disorder (ADHD; traditionally Shire's strongest field). Meanwhile, the additions of Replagal and Elaprase (both from Transkaryotic Therapeutics) have expanded Shire's specialty centred business into the treatment of genetic diseases.
During 2006, Shire reached a key settlement with Barr Pharmaceuticals. The two companies had been involved in patent litigation over Adderall XR, Shire's top-selling product, which has patent protection until 2019. The agreement between the two companies allows Barr to launch its generic Adderall XR product ten years prior to patent expiry, however, it should prevent further patent challenges and limit generic competition until 2019. A key component of this agreement was the granting of a licence to Shire to begin developing Duramed Pharmaceuticals' (a subsidiary of Barr) new oral contraceptive, Seasonique, as well as five other products, which utilise Duramed's transvaginal ring technology. With this licence, Shire could begin to move into yet another new key area of interest, women's health, further expanding what was previously a very limited product portfolio.
Shire's remaining key products are forecast to achieve strong growth within our forecast period, whilst Shire has two more products currently awaiting approval (Intuniv and SPD465) which are expected to become key products for the company.
Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Acquisitions
- Divestitures
- Key Agreements
- Product Performance Forecasts
- Discontinued Products
- Pipeline Analysis
- Discontinued R&D Projects
- Conclusions/Outlook
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- CENTRAL NERVOUS SYSTEM
- Marketed Products
- Adderall/Adderall XR
- Daytrana
- Reminyl
- Vyvanse
- Others
- R&D Projects
- Intuniv
- SPD465
- SPD487
- Growth Forecast
- HUMAN GENETIC THERAPIES
- Marketed Products
- Elaprase
- Replagal
- Others
- R&D Projects
- Amigal
- AT2220
- GA-GCB
- Metazym
- Plicera
- Growth Forecast
- GASTROINTESTINAL
- Marketed Products
- Lialda/Mezavant
- Pentasa
- R&D Projects
- SPD550
- Growth Forecast
- RE NAL
- Marketed Products
- Growth Forecast
- OTHER S
- Marketed Products
- R&D Projects
- Juvista
- Seasonique
- APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2007
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- Alba Therapeutics Corp
- Amicus Therapeutics Inc
- Avexa Ltd
- Barr Pharmaceuticals Inc
- Bristol-Myers Squibb
- Genzyme Corporation
- Giuliani farmaceutici/Cosmo Pharmaceutical SpA
- Impax Laboratories Inc
- Johnson & Johnson
- Mochida Pharmaceutical Co Ltd
- Noven Pharmaceuticals
- Paladin Labs
- Renovo Group plc
- Samaritan Pharmaceuticals
- Takeda
- APPENDIX 4 - INFRASTRUCTURE
- APPENDIX 5 - KEY PHARMACEUTICAL
- SUBSIDIARIES/JOINT VENTURES
- APPENDIX 6 - PRODUCT INDEX
- Index of Tables
- Principal Operating Results
- Sales By Business Area
- Operating Income By Business Area
- Total Assets by Business Area
- Sales By Geographic Area
- Long-lived Assets by Geographical Area
- Recent Product Approvals
- Major Therapeutic Areas And Sales
- Major CNS Products, 2007
- Major HGT Products, 2007
- Major Gastrointestinal Products, 2007
- Major Renal Products, 2007
- Other Products, 2007
- Index of Charts
- R&D Expenditure and Capital Expenditure
- Sales By Business Area, 2007
- Operating Income by Business Area
- Sales By Geographic Area
- Top 10 Selling Product Sales (2002
- A-2012E)
- Top Selling Products, 2007
- Adderall XR Sales (2002A-2012E)
- Daytrana Sales (2002A-2012E)
- Reminyl/Reminyl XL Sales (2002A-2012E)
- Vyvanse Sales (2002E-2012E)
- Intuniv Sales (2008E-2012E)
- SPD465 Sales (2009E-2013E)
- Elaprase Sales (2002A-2012E)
- Replagal Sales (2002A-2012E)
- Lialda/Mezavant Sales (2002A-2012E)
- Pentasa Sales (2002A-2012E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
